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pessary with a cervical cerclage in the
prevention of preterm delivery in women
with short cervical length and a history of
preterm birth – PC study
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Dick J. Bekedam3, Maureen T.M. Franssen4, Sebastiaan W.A. Nij Bijvank5, Marieke Sueters6, Marchien van Baal7,
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Abstract
Background: Preterm birth is in quantity and in severity the most important contributor of perinatal
morbidity and mortality both in well- and low-resource countries. Cervical pessary and cervical cerclage are
both considered as preventive treatments in women at risk for preterm birth. We aim to evaluate whether a
cervical pessary can replace cervical cerclage for preventing recurrent preterm birth in women with a prior
preterm birth due to cervical insufficiency or in women with a prior preterm birth and a short cervix in the
current pregnancy.
(Continued on next page)
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Methods/design: A nationwide open-label multicentre randomised clinical trial will be set up to study women with
a singleton pregnancy and a prior preterm birth before 34 weeks of gestation. Women are eligible in case of previous
preterm birth based on cervical insufficiency (primary intervention, <16 weeks) or in case of previous preterm birth and
a short cervical length in current pregnancy ≤25 mm (secondary intervention, <24 weeks). Eligible women will be
randomised to either cervical pessary or cervical cerclage. Both interventions will be removed at labour or at 36 weeks
of gestational age, whatever comes first. The primary outcome will be delivery before 32 weeks. Secondary outcomes
will be gestational age at birth, preterm birth rate before 24, 28, 34 and 37 weeks of gestation (overall and stratified by
spontaneous or indicated delivery), premature rupture of membranes, use of tocolysis and/or corticosteroids during
pregnancy, mode of delivery, maternal infections, maternal side effects, neonatal and maternal hospital admissions, and
a composite of adverse perinatal outcomes including both morbidity and mortality. We assume an event rate of 20%
preterm birth before 32 weeks for cerclage and use a non-inferiority margin of 10% for the cervical pessary. Using an
alpha of 0.05 and power of 0.80 we need 2 groups of 200 women each.
Discussion: The outcome of this study will indicate the effectiveness and the cost-effectiveness of a cervical cerclage
and of a cervical pessary.
Trial registration: Netherlands Trial Registry, NTR 4415. Date registered: 29th of January 2014.
Keywords: Preterm birth, Prevention, Cerclage, Pessary, Morbidity
Background
Preterm birth is defined as delivery before 37 completed
weeks of gestational age (GA). The incidence of preterm
birth varies between countries with a range of 5–13%
and results in 15 million preterm deliveries worldwide
each year. Preterm birth is a major contributor to peri-
natal mortality. Of all perinatal mortality, 50–70% is
associated with preterm birth [1].
Approximately 75% of all preterm births occur spon-
taneously, starting with either contractions or preterm
pre-labour rupture of membranes (PPROM). Preterm
birth is the leading cause of neonatal morbidity, mostly
due to respiratory immaturity, intracranial haemorrhages
and infections. These conditions can result in long-term
neurodevelopmental sequelae such as intellectual impair-
ment, cerebral palsy, chronic lung disease, deafness and
blindness [2]. Thus, prevention of spontaneous pre-
term birth remains one of the biggest challenges in
obstetric care.
An important risk factor for preterm birth is a prior
preterm birth. Women with a prior spontaneous pre-
term birth before 34 weeks have an average risk of 20%
(range between 15.8% and 30.2%) of recurrence of spon-
taneous preterm birth before 37 weeks and 15% before
34 weeks [3, 4]. Women with a previous preterm birth
before 34 weeks of gestation are usually advised to use
progestagens, either 17-hydroxy progesterone caproate
or vaginal progesterone, in a following pregnancy. Add-
itionally, women with a prior preterm birth due to
cervical insufficiency can be offered a primary cervical
cerclage, i.e. history based cerclage. Cervical insufficiency
is characterized by progressive shortening and dilatation
of the cervix before 24 weeks of gestation without signs
of preterm labour, and is associated with mid-trimester
pregnancy loss and early preterm birth. Screening for
cervical shortening by transvaginal ultrasound before
24 weeks of gestation is recommended in women with a
prior preterm birth without (clear) diagnosis of cervical
insufficiency in prior pregnancies. In case of a short cer-
vix ≤25 mm before 24 weeks of gestational age, these
women can be offered a secondary cervical cerclage, i.e.
ultrasound indicated cerclage [5].
A cervical cerclage is a surgical procedure that
involves occlusion of the cervix by means of a cervical
suture or stitch which is performed under general or
spinal anaesthesia proposed by Shirodkar in 1955 [6]
and by McDonald in 1957 [7]. A primary cerclage is
considered to be effective in the prevention of preterm
birth in women with cervical insufficiency and is usually
offered before 16 weeks of gestational age. The largest
trial published in 1993 included 1292 women with
singleton pregnancies, and showed a significant reduc-
tion in preterm birth before 33 weeks of gestation (13%
versus 17%; P = 0.03) [8]. A meta-analysis from 2003
demonstrates that primary cervical cerclage has a signifi-
cant effect in preventing spontaneous preterm birth be-
fore 34 weeks of gestation [9]. The effectiveness of a
secondary cerclage has been studied in a meta-analysis
from 2011. This meta-analysis found that in these
women the risk of delivery before 32 weeks’ gestation
was 19% in women with cerclage as compared to 30% in
those without cerclage (RR 0.66 95% CI 0.48–0.91) [10].
Placement of cervical cerclages has proven to be
effective in some women at risk for recurrent preterm
birth. However, the disadvantage of cervical cerclage is
the potential harm. Complications of cervical cerclage
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include PPROM, preterm labour, infection, suture dis-
placement, and bleeding [11]. In addition, cerclage is
associated with an increased risk of cervical lacer-
ation, both in nulliparous (OR 3.7, 95% CI 1.1–12.8)
and multiparous women (adjusted OR 12.7, 95% CI
5.7–28.2) [12].
The cervical pessary is a soft and flexible silicone
device known since 1959 when it was used in women
with recurrent miscarriage [13]. Although the exact
mechanism of the cervical pessary remains unknown, it
has been hypothesised that the pessary relieves direct
pressure on the internal cervical ostium by changing the
position of the cervical canal and distributing the weight
of the pregnant uterus [14]. Another possible mechan-
ism is that the pessary might support the immunological
barrier between chorioamnion-extraovular space and the
vaginal microbiological flora [15]. Recently, several
randomised trials showed that the cervical pessary may
be potentially effective as a treatment for preterm birth
prevention. The Spanish Pesario Cervical para Evitar
Prematuridad (PECEP) trial from 2012 compared treat-
ment with a pessary in women with a short cervix with
expectative management and showed a significant de-
crease in preterm birth before 34 weeks of gestation (OR
0.19; 95% CI 0.12–0.30) and improvement of neonatal
outcome (RR 0.14; 95% CI 0.04–0.39) in the intervention
(pessary) group. In this study, 11% of 385 women included
had at least one prior preterm birth, however, no sub-
group analysis was performed for women with a previous
preterm birth [15]. The same group performed a similar
trial in twin pregnancies and observed a reduction in
spontaneous preterm birth before 34 weeks of gestation in
the pessary group (16.2% versus 25.7%; p 0.0001) [16].
Another randomised controlled trial performed by
Liem et al. in 2014 comparing a pessary with no treat-
ment in twin pregnancies showed similar results in a sub-
group with short cervix [17]. Two randomised trials
coordinated by the Fetal Medicine Network from the
United Kingdom could not confirm these results of the
pessary, both in singleton and multiple pregnancies with
short cervix [18, 19]. The most frequently reported side
effect of a pessary is vaginal discharge. Less common
reported complications during the use of a pessary are
vaginal blood loss or pelvic pain. Cervical laceration as
complication is rarely seen in the use of pessary, this
chance seems smaller than 0.1%.
Since a cervical pessary can be positioned in an out-
patient setting, it is less expensive than placing a surgical
cerclage and is therefore potentially more attractive than a
cerclage. In addition, a cervical pessary is a non-invasive
method contrary to a cervical cerclage which is an invasive
procedure. Although both interventions have been
available for over 55 years now, both interventions have
been compared directly only once. A randomised study
performed in 1986 in Germany in women with a prior
preterm birth included 242 women and did show compar-
able outcomes in women using a pessary and women
having cerclage (37 + 5 weeks of gestational age at delivery
in the cerclage group versus 37 + 1 weeks in the pessary
group, p value not significant) [20].
We propose to compare the cervical pessary and
cervical cerclage in a head-to-head comparison and
hypothesise that the use of a cervical pessary will be
equally effective in preventing preterm birth as cervical
cerclage. The outcome of the proposed study will indi-
cate the relative effectiveness of cervical pessary for
women with a singleton pregnancy with a prior preterm
birth due to cervical insufficiency and in women with a
prior preterm birth and short cervical length in current
pregnancy. In addition, we will be able to compare the
costs of both interventions. Since the placement of a
pessary is less expensive compared to the surgical appli-
cation of a cerclage, implementation of this therapy will
potentially yield a major cost-reduction.
Methods/design
Aim, design and setting
We will perform an international randomised controlled
trial under the acronym the PC Study (Pessary or Cerclage
to prevent preterm delivery in women with short cervical
length and a history of preterm birth; Netherlands Trial
Registry NTR 4415, registered at the 29th of January 2014:
website http://www.trialregister.nl/trialreg/admin/rctvie-
w.asp?TC=4415). The study will assess the effect of a cer-
vical pessary on preterm birth rates and neonatal outcome
compared to treatment with a cervical cerclage. The study
is set in the Dutch Consortium for Healthcare Evaluation
and Research in Obstetrics and Gynaecology - NVOG
Consortium 2.0, a collaborative network of all major
hospitals in The Netherlands and the Dutch Society of
Obstetrics and Gynaecology (NVOG). In addition, inter-
national hospitals interested in the trial can participate in
this study.
Participants
According to local protocols, asymptomatic women with
a singleton pregnancy and a prior spontaneous preterm
birth before 34 weeks of gestation are offered the use of
progesterone and cervical length measurements before
24 weeks of gestation. Women with a cervix ≤25 mm
before 24 weeks of gestation are eligible to participate in
the trial as these women would be eligible for a second-
ary cerclage. Additionally, women who are considered
for a placement of a cerclage before 16 weeks gestation
based on their obstetric history of cervical insufficiency
(primary cerclage) are eligible.
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Eligibility criteria
All women with an indication for a primary or second-
ary cerclage, as described above, are eligible to partici-
pate in this study. Women with placenta praevia, vasa
praevia, PPROM, cervical length of less than 2 mm,
cervical dilation of 3 cm or more, identified major con-
genital or chromosomal abnormalities and women with
signs of intrauterine infection will be excluded from the
study. In addition, maternal age less than 18 years and
inability to give informed consent are exclusion criteria.
Procedures, recruitment, randomisation and collection of
baseline data
All eligible women will be informed in brief about the
clinical trial by the supervising gynaecologist or by the
attending resident. Subsequently, the investigator or an
authorised member of the investigational staff must
explain to potential subjects the aims, methods, reason-
ably anticipated benefits, and potential hazards of the
study. Women will be informed that their participation is
voluntary and that they may withdraw consent to partici-
pate at any time. They will be informed that choosing not
to participate will not affect the care they will receive.
Each woman must give written consent prior to
randomisation. The woman will be given sufficient time
to read the patient information and the informed con-
sent form and have the opportunity to ask questions. An
independent physician will be accessible for any ques-
tions the women may have. The consent form must be
signed before any study-related activity can take place. A
copy of the informed consent form must be given to the
participating woman. Patient information is provided in
Dutch and English. Women who meet all inclusion
criteria but decline to participate are asked to be
included in an observational cohort (see Figure 1).
Randomisation will be centrally controlled using an on-
line computerised randomisation service made specifically
for randomization in clinical trials, ALEA (https://nl.tena-
lea.net/amc/ALEA/). Centres will be able to access the
randomisation service 24 h/day. Eligible women will be
randomized in a 1:1 ratio to cervical cerclage and pessary
(see Figure 1). Randomisation will be stratified by indica-
tion for type of cerclage (primary or secondary) and centre
(to prevent any imbalance between groups in aspects of
maternal or neonatal care that may differ between cen-
tres). We will apply block randomisation with a variable
block size of 4 and 6. Due to the type of interventions this
study will not be blinded.
Baseline characteristics (e.g. patient demographics,
obstetric and medical history), details of delivery, mater-
nal and neonatal assessments during pregnancy or post-
partum will be recorded into a web-based Case Report
Form (CRF) that is accessible through a closed part of a
web-secured database (see Figure 1). We included core
outcomes for preterm birth in the CRF [21]. The CRF
can be found in Additional file 1.
Confidentiality and data security
Initials of participants as well as year of birth are
recorded in the electronic database. Linking personal
data with randomisation number can only be done in
the local clinics. Each participating clinic receives a login
name and password to gain access to the web-secured
database. The access is restricted to the database of the
clinic to which the password and login name belongs.
Full access to the entire database is possible to some
members of the research staff, but has to be requested
via the trial bureau and data manager of the NVOG
Consortium 2.0.
Intervention
Eligible women will be randomly allocated to receive
either a cervical cerclage or a cervical pessary (Arabin®
pessary). Both will be placed before 24 weeks, or before
16 weeks in case of a primary intervention. Women allo-
cated to a cervical cerclage will be receiving the inter-
vention according to local protocol. Women allocated to
a cervical pessary will receive a simple vaginal examin-
ation to assess which size pessary fits best. It is import-
ant that the pessary is placed by a care giver with
expertise to ensure careful placement of the pessary. In
case of complaints, (vaginal) examination of the patient
is advised to reposition the pessary or to replace the pes-
sary with another size if necessary. Both interventions
will stay in place until 36 weeks of gestation or until
delivery, whatever comes first. If recurrent or persistent
blood loss, premature rupture of the membranes or con-
tractions occur during the use of a pessary, the pessary
should be removed. Further management will be accord-
ing to the national guideline on prevention of preterm
birth and local protocols (see Figure 1).
Outcome measures
Primary outcome measure
The primary outcome will be delivery before 32 weeks
of gestation.
Secondary outcome measures
Secondary outcomes will be time from intervention to
delivery, gestational age at birth, preterm birth rate
before 24, 28, 34 and 37 weeks of gestation (overall and
stratified by spontaneous or indicated delivery), prema-
ture rupture of membranes, use of tocolysis and/or
corticosteroids during pregnancy, mode of delivery,
maternal infections, maternal side effects and both neo-
natal and maternal hospital admissions. Perinatal outcome
will be assessed through a composite of adverse perinatal
outcome. This composite outcome contains chronic lung
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disease, intraventricular haemorrhage (IVH) > grade II,
periventricular leucomalacia (PVL) > grade I, necrotising
enterocolitis (NEC) > stage I, retinopathy of prematurity
(ROP), patent ductus arteriosus (PDA), treated seizures,
early and late onset sepsis, neonatal meningitis,
(intra-partum) stillbirth, death before discharge from
the nursery. The definitions of these outcomes can be
found in Table 1. All components of the composite
outcome will also be assessed individually.
In addition, a cost-effectiveness analysis will be
performed that will be reported separately from the
primary report on the randomised trial.
Fig. 1 Flow diagram PC Study
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Follow up of women and infants
All details of delivery, maternal assessments and admit-
tance during pregnancy will be recorded in an electronic
case record form that will be accessible through the
web-secured database. In case of admittance of a new-
born, details of admittance will also be recorded. The
outcome measures, when applicable, will be measured
until 10 weeks after the expected term date of delivery.
The possibilities to perform long term follow-up will
be assessed and planned, depending on the outcomes of
the primary study and granted funding. Permission to
approach women for follow-up research will be asked by
the initial informed consent.
Statistical issues
Sample size
We plan to evaluate the non-inferiority of a cervical
pessary as compared to cervical cerclage. We assume an
event rate of 20% for the primary outcome, i.e. delivery
before 32 weeks, for cerclage based on current literature.
We will use a non-inferiority margin of 10%. If the event
rate is 20% for the primary outcome in the cerclage arm,
this is equivalent to saying that a pessary is non-inferior to
cerclage when the upper limit of the 95% confidence inter-
val of the event rate of the primary outcome in the pessary
group is less than 30%. Using a one-sided alpha of 0.05
and power of 0.80 we need 2 groups of 200 women each.
Data analysis
Data will initially be analysed according to the intention to
treat method. The primary outcome will be assessed
investigating whether the prevalence of the primary out-
come, birth before 32 weeks, is not more than 10% higher
in the pessary group compared to the cerclage group.
Non-inferiority will be concluded when the upper end
of a one-sided 95% confidence interval for the risk
difference between the prevalence of the primary
outcome in the pessary group and the cerclage group
is less than 10%.
The secondary outcome time from intervention to
delivery will be evaluated by Cox proportional hazard
analysis and Kaplan-Meier estimates and plots, with
account for different durations of gestation at entry and
stratification by indication for intervention (and centre
when data allows), and will be tested with the log rank
test. Secondary dichotomous outcome measures will be
assessed by calculating absolute and relative risks, along
with 95% confidence intervals. Differences in continuous
outcomes between both strategies will be assessed using
a linear mixed model.
In all analyses, stratification by centre will be accounted
for with a random intercept for each centre, and by
adding the cerclage indication as a covariate to the
log-binomial or linear mixed models. If these models
fail, A Cochran–Mantel–Haenszel (CMH) approach
will be used to take into account that randomisation
was stratified on indication for cerclage (and centre, if
the data allows). Such a stratified analysis of the esti-
mates the risk differences from each covariate sub-
group and uses CMH weights to estimate treatment
difference and its standard error. When appropriate,
numbers needed to treat will be calculated.
Table 1 Definitions of secondary outcome measures
Outcome Defined as:
Maternal infections Two measurements of maternal temperature above 37,8 degrees Celsius at a one hour interval and a maternal
pulse >100 beats per minute requiring treatment with antibiotics
Maternal side effects Vaginal discharge, bleeding, discomfort, dyspareunia, cervical laceration
Chronic lung disease Babies born before 32 weeks: need for >30% oxygen, with or without positive pressure ventilation or continuous
positive pressure at 36 weeks postmenstrual age, or discharge (whichever comes first).
Babies born after 32 weeks: need for >30% oxygen with or without positive pressure ventilation or continuous
positive pressure at 56 days postnatal age, or discharge (whichever comes first).
IVH > grade II Haemorrhage in the germinal matrix, ventricles, or cerebral parenchyma; observed on ultrasound examination
or MRI
PVL > grade I Periventricular lucency in the white matter
NEC > stage I Defined as the presence of the characteristic clinical features of abdominal distension, with or without rectal
bleeding, and abdominal radiographic finding associated with pneumatosis intestinalis
Early sepsis If prior to or at 72 h of life the infant had an infection marked by positive blood, CSF, or urine (catheterised or
suprapubic) cultures with or without suspicious clinical findings of infection on physical examination.
Late sepsis If after 72 h of life the infant had an infection marked by positive blood, CSF, or urine (catheterised or
suprapubic) cultures with or without suspicious clinical findings of infection on physical examination
OR
if there is clinical evidence of cardiovascular collapse or an unequivocal X-ray confirming infection and often
cardiovascular decomposition
Neonatal meningitis Suspected or proven (caused by any pathogen)
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Subgroup analysis
We pre-specify three subgroup analyses based on: (1)
the indication of the type of cerclage to investigate the
effectiveness of the pessary compared to a primary and
secondary cerclage separately, (2) the number of previ-
ous preterm births (overall and separately for indication
for primary or secondary intervention) in which we dis-
tinguish those with one previous preterm birth from
those with two or more previous preterm births and (3)
cervical length ≤15 mm and >15 mm in women with an
indication for secondary intervention. Subgroup effects
will be investigated for the primary outcome, preterm
delivery before 32 weeks of gestation, and for the com-
posite of perinatal outcome. Subgroup effects will be
assessed by including an interaction term between the
subgrouping variable and treatment allocation as covari-
ate to the regression model. Afterwards, a stratified sub-
group analysis will be performed to study the effect of
treatment in different strata of the subgroups.
To evaluate the potential of each of the strategies, we
will also perform a per protocol analysis, taking into
account only those cases that were treated according to
protocol.
Safety
(Serious) Adverse Event ([S]AE)
All AEs reported spontaneously by the subject or
observed by the investigator or his staff will be recorded.
All SAEs will be reported through the web portal
ToetsingOnline to the accredited medical ethics com-
mittee (MEC) that approved the protocol.
Interim safety review
Safety reviews will be performed after all outcomes of
110 inclusions are available for analysis, and thereafter
as determined necessary by the independent data and
safety monitoring board (DSMB). The DSMB will be
unblinded before making recommendations, but the
researchers are to remain blinded. An extra meeting will
be planned if indicated by the safety review. The data
and safety monitoring committee can advise to stop the
study for safety reasons.
Discussion
To our knowledge there are no other registered on-going
trials comparing the effect of a cervical pessary and a
cervical cerclage in women at high risk for preterm birth.
When the pessary was first described in 1959, it was
used in women with recurrent late miscarriages and pos-
sible cervical insufficiency [13]. The largest randomised
controlled trial so far shows no difference between cer-
vical cerclage and pessary in women with previous spon-
taneous preterm birth and an indication for a cerclage
[20]. In addition, the recent PECEP study, a study which
compared treatment with a pessary in women with a
short cervix with expectative management, included 11%
women with at least one prior preterm birth. This study
showed an overall significant decrease in preterm birth
in the intervention (pessary) group (spontaneous deliv-
ery before 34 weeks 12 (6%) in the pessary group vs. 51
(27%) in de control group; OR 0.18; 95% CI 0.08–0.37;
p < 0·0001), however, no subgroup analysis was per-
formed for women with a previous preterm birth [15].
There are clues that a cervical pessary might be as
effective as a cerclage in the prevention of preterm birth,
however, large recent randomized controlled trials with
information on the effectiveness of a pessary in women
with a previous preterm birth are lacking.
A cervical cerclage is considered to be effective in the
prevention of preterm birth in women with cervical
insufficiency and/or short cervix during pregnancy with
a previous preterm birth. However, it is associated with
serious risks such as premature rupture of membranes,
premature contractions, cervical and/or uterine infec-
tions, vaginal bleeding and cervical laceration [11, 12].
Although the chance of these complications occurring is
indeed low, the impact on the course of the pregnancy is
major. Additionally, cervical cerclage is a surgical inter-
vention which is usually performed under general anaes-
thesia, and as such is at risk of surgical complications. A
cervical pessary is a non-invasive intervention and can
be placed in an outpatient setting. In addition, severe
complications related to cerclage are considered to occur
more often compared to complications related to the
use of pessary. This makes a pessary more attractive as
intervention, however, the effect on preterm birth and
neonatal outcome should be addressed first.
The outcome of this study will determine whether
treatment with a cervical pessary can replace a cerclage
to prevent preterm birth in women at high-risk for
preterm delivery.
Additional files
Additional file 1: Case Report Form (CRF) PC Study. (DOCX 155 kb)
Additional file 2: SPIRIT checklist for reporting randomised trials for the
PC Study. (DOC 120 kb)
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